Reports - Fusion Biopsy Market
Fusion Biopsy Market Size, Share & Trends Analysis Report by Biopsy Route (Transrectal, Transperineal) by End-Use (Hospitals, Diagnostic Centers, Ambulatory Care Centers) by Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) - Historic Data (2021 - 2023) & Forecast Period (2025 - 2035)
Industry Leaders Trust Us For Actionable Intelligence
USD 736.6 Million
USD 1849 Million
8.75%
Asia Pacific
Asia Pacific
2024
2021 - 2023
2025 - 2035
By Biopsy Route, By End-Use, By Region
The final deliverable will encompass both quantitative and qualitative data, providing a comprehensive analysis of the market. The scope is customizable.
The global Fusion Biopsy Market is valued at USD 736.6 Million in 2024 and is projected to reach a value of USD 1849 Million by 2035 at a CAGR (Compound Annual Growth Rate) of 8.75% between 2025 and 2035.
Premium Insights
Fusion Biopsy, a combination of MRI and ultrasound image guidance, offers improved detection and targeting of prostate cancer. Studies have shown a significant increase in the detection of clinically significant tumors using this approach. For example, a study published by the National Cancer Institute (NCI) showed that targeted MR/US Fusion Biopsy diagnosed 30 percent more high-risk cancers than standard biopsy and 17 percent fewer low-risk cancers. With improved accuracy and precision, Fusion Biopsy presents substantial opportunities to enhance early detection and better manage prostate cancer.
Top Market Trends
Economic Insights
The government and commercial organizations are committed to enhancing the health outcomes of men with prostate cancer by investing in research and developing precise and timely diagnostic methods. Notably, the Australian government has allocated more than USD 84 Million towards prostate cancer treatment and diagnostic research since 2013 through initiatives such as Cancer Australia, Prostate Cancer Research Foundation Australia, and National Health Medical Research Council Australia. Similarly, the United Kingdom government announced a budget of USD 19 Million in October 2018 to acquire advanced diagnostic scanners and train radiologists to provide better medical services for prostate cancer patients.
Market Segmentation
The Global Fusion Biopsy Market can be broadly classified into the below-mentioned segments:
{{Segmentation_Ext}}
Based on the Biopsy Route
Transrectal to Lead Maximum Market Share Due to the Use of High-Strength Adhesives Used for the Bonding of Planks
The Fusion Biopsy market is segmented into the transrectal biopsy route and the transperineal biopsy route. In 2022, the transrectal biopsy route accounted for a sizable market share because it was considered the gold standard in performing prostate biopsy worldwide in the past decades. Most commercially available Fusion Biopsy was limited to the transrectal approach, contributing to its most significant market share. However, the transperineal biopsy route will increase significantly between 2023 and 2030.
Based on End-use
The Hospitals segment Expects Dominion Owing to The Availability of Highly Skilled Professionals and Better Facilities
The Fusion Biopsy market is segmented based on the End-Users into hospitals, diagnostics, and ambulatory care centers. The hospitals segment is responsible for the largest market share in 2022, while the mobile care centers segment is expected to grow fastest during the forecast period. The growing prevalence of prostate cancer in rural areas with restricted access to healthcare services is expected to drive the segments growth.
Based on Region
North America to Dominate Global Sales Owing to The Growing Prevalence of Prostate Cancer and the Presence of Well-established Healthcare Facilities
North America dominated the industry in 2022 with a market share of 46.2% on account of the rising cases of prostate cancer. The region is expected to dominate the market due to better healthcare infrastructure and facilities. Further, the increasing research and development expenditure for prostate cancer has led to the growth of the region’s Fusion Biopsy market.
The Asia Pacific region is expected to witness the fastest growth in the Fusion Biopsy market. The major factors boosting the markets growth include increasing awareness of prostate cancer, a growing population base, rising disposable income levels, and high unmet needs of patients in emerging countries such as India, Japan, and China. Thus, the rising demand for diagnosis within the region is expected to propel market growth.
Competitive Landscape
The Fusion Biopsy market is highly competitive, with several significant players vying for market share. For example, Philips Healthcare offers the UroNav system, which has a 97% detection rate for clinically significant prostate cancers. Similarly, GE Healthcare provides the LOGIQ E9 system, which offers real-time image fusion to target lesions accurately. These players constantly innovate and invest in research and development to stay ahead in the competitive market.
The key players in the global Fusion Biopsy market include - Eigen Technologies (U.S.) among others.
Recent Market Developments
Segmentation of the Global Fusion Biopsy Market
Parameter | Details |
---|---|
Segment Covered | By Biopsy Route
By End-Use
By Region
|
Companies Covered |
|
Customization Scope | Enjoy complimentary report customization—equivalent to up to 8 analyst working days—with your purchase. Customizations may include additions or modifications to country, regional, or segment-level data. |
Pricing and purchase options | Access flexible purchase options tailored to your specific research requirements. Explore purchase options |
Key features include:
Contact
Toll Free Number+1 (877) 462-2282